Medicare Enrolled
Dr. Idelfia Marte, M.D.
Hematology · Clearwater, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Marte from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Marte? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Marte
Dr. Idelfia Marte is a hematology in Clearwater, FL, with 19 years in practice. Based on federal Medicare data, Dr. Marte performed 83,744 Medicare services across 2,768 unique beneficiaries.
Between the years covered by Open Payments, Dr. Marte received a total of $17,950 from 67 pharmaceutical and/or device companies across 470 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Marte is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ 83,744 Medicare services$ $17,950 industry payments
Medicare Practice Summary
Medicare Utilization ↗83,744
Medicare services
Bottom 49% in FL for hematology
2,768
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,408 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 39,270 | $0 | $4 |
| Filgrastim injection (Zarxio) for white blood cells | 16,080 | $0 | $2 |
| Anti-nausea injection (aprepitant) | 6,370 | $1 | $5 |
| Iron sucrose injection (Venofer) | 4,700 | $0 | $5 |
| Epoetin alfa injection (Procrit) for anemia | 3,980 | $6 | $23 |
| Denosumab injection (Prolia/Xgeva) | 2,460 | $18 | $51 |
| Complete blood count (CBC) with differential | 1,738 | $8 | $29 |
| Blood draw (venipuncture) | 1,573 | $8 | $9 |
| Dexamethasone injection (steroid) | 1,133 | $0 | $3 |
| Office visit, established patient (30-39 min) | 843 | $93 | $339 |
| Anti-nausea injection (Aloxi/palonosetron) | 760 | $1 | $28 |
| Drug injection, under skin or into muscle | 728 | $10 | $69 |
| Anti-nausea injection (ondansetron/Zofran) | 664 | $0 | $9 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 437 | $1 | $6 |
| Office visit, established patient, complex (40-54 min) | 361 | $136 | $474 |
| Office visit, established patient (20-29 min) | 316 | $67 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 288 | $22 | $84 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 244 | $1 | $7 |
| Administration of chemotherapy into vein, 1 hour or less | 209 | $98 | $378 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 201 | $47 | $189 |
| Injection, carboplatin, 50 mg | 163 | $2 | $41 |
| Infusion into a vein for hydration, 31-60 minutes | 156 | $24 | $156 |
| Injection of additional new drug or substance into vein | 143 | $12 | $61 |
| Infusion into a vein for hydration, each additional hour | 128 | $10 | $42 |
| Injection, diphenhydramine hcl, up to 50 mg | 127 | $1 | $3 |
| Administration of chemotherapy into vein, each additional hour | 113 | $22 | $79 |
| Hospital follow-up visit, high complexity | 87 | $94 | $285 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 71 | $16 | $56 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 71 | $17 | $59 |
| Administration of additional new drug or substance into vein, 1 hour or less | 66 | $49 | $178 |
| Injection of drug or substance into vein | 52 | $28 | $156 |
| Initial hospital admission, high complexity | 44 | $137 | $556 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 41 | $3 | $11 |
| New patient office visit (45-59 min) | 39 | $125 | $453 |
| Infusion, normal saline solution , 1000 cc | 34 | $2 | $7 |
| Red blood count, automated test | 31 | $4 | $10 |
| New patient office visit, complex (60-74 min) | 23 | $160 | $585 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
48.2% high complexity
45.6% medium
6.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,950
Total received (2018-2024)
Avg $2,564/year across 7 years
Top 27% in FL for hematology
67
Companies
470
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,755 (54.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,802 (26.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,393 (18.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,040
2023$3,182
2022$4,755
2021$1,213
2020$690
2019$4,416
2018$1,656
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Daiichi Sankyo Inc.
$3,672
Verastem, Inc.
$2,670
Janssen Biotech, Inc.
$1,987
Novartis Pharmaceuticals Corporation
$1,017
PFIZER INC.
$731
GENZYME CORPORATION
$727
Celgene Corporation
$610
E.R. Squibb & Sons, L.L.C.
$462
Gilead Sciences, Inc.
$432
Pharmacyclics LLC, An AbbVie Company
$405
AstraZeneca Pharmaceuticals LP
$387
Seagen Inc.
$380
Amgen Inc.
$339
Lilly USA, LLC
$311
Genentech USA, Inc.
$309
Merck Sharp & Dohme LLC
$301
GlaxoSmithKline, LLC.
$236
Takeda Pharmaceuticals U.S.A., Inc.
$225
Exelixis Inc.
$195
ARRAY BIOPHARMA INC
$147
BeiGene USA, Inc.
$144
ABBVIE INC.
$137
Incyte Corporation
$133
TESARO, Inc.
$128
Eisai Inc.
$128
Genmab U.S., Inc.
$125
Dova Pharmaceuticals
$125
Epizyme, Inc.,
$108
Rigel Pharmaceuticals, Inc.
$107
SANOFI-AVENTIS U.S. LLC
$100
Progenics Pharmaceuticals, Inc.
$98
Merck Sharp & Dohme Corporation
$95
Taiho Oncology, Inc.
$85
Kite Pharma, Inc.
$76
AbbVie, Inc.
$60
Astellas Pharma US Inc
$48
JAZZ PHARMACEUTICALS INC.
$46
Boehringer Ingelheim Pharmaceuticals, Inc.
$45
TAIHO ONCOLOGY, INC.
$39
Genentech, Inc.
$38
Bayer Healthcare Pharmaceuticals Inc.
$35
Myovant Sciences Inc.
$35
Array BioPharma Inc.
$34
Pharmacyclics LLC, an AbbVie Company
$31
Puma Biotechnology, Inc.
$29
Spectrum Pharmaceuticals Inc.
$29
Myriad Genetic Laboratories, Inc.
$27
Regeneron Healthcare Solutions, Inc.
$26
EMD Serono, Inc.
$23
Alnylam Pharmaceuticals Inc.
$23
Seattle Genetics, Inc.
$23
PUMA BIOTECHNOLOGY, INC.
$20
Janssen Pharmaceuticals, Inc
$17
Ipsen Biopharmaceuticals, Inc
$17
Hologic Sales and Service, LLC
$17
PharmaEssentia USA Corporation
$16
Deciphera Pharmaceuticals Inc.
$16
Kyowa Kirin, Inc.
$16
Secura Bio, Inc.
$15
MEDIVATION FIELD SOLUTIONS LLC
$15
Advanced Accelerator Applications
$15
CTI BioPharma Corp.
$15
Helsinn Therapeutics (U.S.), Inc.
$15
Blueprint Medicines Corporation
$13
Acrotech Biopharma LLC
$12
Clovis Oncology, Inc.
$12
Veracyte, Inc.
$1
Top 3 companies account for 46.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALUNBRIG · AYVAKIT · Alecensa · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · Bavencio · Beleodaq · Braftovi · CABOMETYX · CALQUENCE · CERDELGA · CEREZYME · COPIKTRA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMEND · ENHERTU · Enhertu · Epkinly · Fabhalta · Folotyn · GAUCHER-DISEASE · GAZYVA · GILOTRIF · GIVLAARI · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · MYOSURE TISSUE REMOVAL DEVICE · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYLARIFY · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · Repatha · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SUTENT · Stivarga · TABRECTA · TASIGNA · TAZVERIK · TECENTRIQ · TUKYSA · Trodelvy · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vonjo · XALKORI · XARELTO · XTANDI · Yescarta · ZEJULA · ZEPZELCA · ZYKADIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (54%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $21 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
41
Per 100K population
4.3
County median income
$70,293
Nearest hospital
MEASE COUNTRYSIDE HOSPITAL
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Marte is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Marte experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Marte performed 39,270 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Marte receive payments from pharmaceutical companies?
Yes. Dr. Marte received a total of $17,950 from 67 companies across 470 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Marte's costs compare to other hematologys in Clearwater?
Dr. Marte's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Marte) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Clearwater
Browse hematologys in Clearwater ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc..
By company
Verastem, Inc. Payments to Doctors
See all physicians who received payments from Verastem, Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology